Clinical Trial Update: Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating trastuzumab deruxtecan-based therapy with rilvegostomig versus standard of care for advanced HER2-expressing biliary tract cancer is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Rilvegostomig (rilvegostomig)
• T-DXd (trastuzumab deruxtecan) (trastuzumab deruxtecan)

Snippet

Sponsor: AstraZeneca | Conditions: Biliary Tract Cancer | Phase 3 | Status: RECRUITING